Indian Gram Positive Bacterial Infections Market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Gram-positive bacteria are responsible for infecting humans and animals with variety of acute and chronic diseases. These bacteria can cause various infectious diseases such as MRSA, pneumonia, sepsis, sinusitis, cellulitis, pharyngitis, impetigo, etc. For, treatment of this infection diseases several antibiotic and antifungal drugs are introduce in the gram positive infectious market like B-Lactam, quinolones, macrolides, tetracycline, aminoglycosides, sulphonamides and phenicols. Antibiotics are widely used as the first line of treatment for these infections. Antibacterial resistance is considered to be effective way for the treatment of bacterial infections.
The factors such as Growing incidence of various gram positive bacterial infections, increasing R&D activities, increasing awareness about infectious diseases rising investment in healthcare, rapidly increasing in antibacterial resistance, rising government initiatives, increasing investment in R&D activities, newer bacterial infection treatment and infection control in healthcare settings are majorly drive the growth of gram positive bacterial infection market. However, the factors that restrain the growth of gram positive bacterial infection such as stringent government regulation, high cost of treatment and R&D, ignorance towards the symptoms, etc.